OHR Pharmaceutical (OHRP) Sets New 1-Year High and Low on Earnings Beat

OHR Pharmaceutical Inc (NASDAQ:OHRP) hit a new 52-week high and low on Tuesday following a better than expected earnings announcement. The company traded as low as $0.20 and last traded at $0.20, with a volume of 212065 shares trading hands. The stock had previously closed at $0.20.

The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02.

Separately, ValuEngine raised OHR Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

An institutional investor recently raised its position in OHR Pharmaceutical stock. Wedbush Securities Inc. lifted its position in shares of OHR Pharmaceutical Inc (NASDAQ:OHRP) by 53.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 662,909 shares of the biotechnology company’s stock after buying an additional 230,950 shares during the quarter. Wedbush Securities Inc. owned approximately 1.18% of OHR Pharmaceutical worth $1,233,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.94% of the company’s stock.

The company has a market capitalization of $11.40 million, a PE ratio of -0.36 and a beta of 0.14.

OHR Pharmaceutical Company Profile

OHR Pharmaceutical, Inc, a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.

Receive News & Ratings for OHR Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OHR Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply